Byetta Lawsuit News: Plaintiffs in Federal Diabetes Drug Litigation...
The Firm is evaluating Byetta lawsuits and other product liability claims that allege incretin mimetic diabetes drugs caused patients to develop pancreatic cancer, pancreatitis and thyroid cancer.(PRWeb November 11, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb12318604.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 12, 2014 Category: Pharmaceuticals Source Type: news
Diabetes Drug Claims Near 550 Mark in Incretin Mimetic Litigation,...
The Firm is investigating Byetta lawsuits and other legal claims that allege pancreatic cancer, pancreatitis and thyroid cancer caused by incretin mimetics, a Type 2 diabetes drug class.(PRWeb November 02, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb12294498.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 2, 2014 Category: Pharmaceuticals Source Type: news
Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics...
The Firm is evaluating Byetta lawsuits and other legal claims that allege the use of diabetes drugs called incretin mimetics caused patients to develop pancreatic cancer, pancreatitis or thyroid...(PRWeb October 08, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb12234584.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - October 9, 2014 Category: Pharmaceuticals Source Type: news
Byetta Lawsuits Move Forward, With New Ruling Issued in Federal...
The Firm is evaluating Byetta lawsuits and other product liability claims that allege incretin mimetic diabetes drugs caused patients to develop pancreatic cancer, pancreatitis and thyroid cancer.(PRWeb September 24, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb12196939.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 25, 2014 Category: Pharmaceuticals Source Type: news
Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics...
The Firm is evaluating Byetta lawsuits on behalf of individuals who developed pancreatitis, pancreatic cancer or thyroid cancer allegedly due to their use of Byetta or other incretin mimetic Type 2...(PRWeb September 11, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb12163899.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 12, 2014 Category: Pharmaceuticals Source Type: news
Byetta Lawsuit News: New Order Establishes Deposition Protocol For...
The Firm is investigating Byetta lawsuits and other legal claims that allege incretin mimetics like Byetta, Januvia and Victoza caused patients to develop pancreatic cancer, pancreatitis or thyroid...(PRWeb August 10, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb12083571.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - August 10, 2014 Category: Pharmaceuticals Source Type: news
Diabetes Drug Eyed as Obesity TreatmentDiabetes Drug Eyed as Obesity Treatment
Already approved for the treatment of diabetes, the incretin mimetic liraglutide is now being investigated as a potential weight-loss drug. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 26, 2014 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Featured in NEJM Journal Watch: Incretin-Based Diabetes Drugs Aren't Associated with Excess Risk for Acute Pancreatitis (FREE)
Extract
Although not the final word, results of two large studies in BMJ should be reassuring for patients taking exenatide (Byetta) and sitagliptin (Januvia... (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - May 8, 2014 Category: Primary Care Source Type: news
Incretin-Targeting Diabetic Drugs: FDA & EMA See No Apparent Pancreatic Harms (FREE)
By Joe Elia
Drugs targeting the insulin-releasing effects of the hormone incretin, such as exenatide (Byetta) and sitagliptin (Januvia), cause no apparent increase in pancreatic side effects, according to a … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - February 28, 2014 Category: Primary Care Source Type: news
As Byetta Lawsuits Move Forward, Bernstein Liebhard LLP Notes New FDA...
The Firm is evaluating Byetta lawsuits and other legal claims on behalf of individuals who allegedly developed pancreatic cancer, pancreatitis, and thyroid cancer due their use of incretin mimetic...(PRWeb February 13, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb11583185.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 14, 2014 Category: Pharmaceuticals Source Type: news
Byetta Lawsuits Move Forward, as Federal and State Incretin Mimetics...
The Firm is investigating Byetta lawsuits that allege an association between the use of Byetta and pancreatic cancer, as well as pancreatitis and thyroid cancer.(PRWeb January 25, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb11521828.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 25, 2014 Category: Pharmaceuticals Source Type: news
The Cardiovascular Safety of Incretin-Based TherapiesThe Cardiovascular Safety of Incretin-Based Therapies
Do controlled trials find that 'gliptins' increase risk for adverse cardiac events? Cardiovascular Diabetology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 2, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
Incretin Safety Data to Highlight EASD Meeting
BARCELONA (MedPage Today) -- Researchers are anticipating a deeper dive into data from safety trials of two DPP-4 inhibitors with a focus on diabetes outcomes and complications, including pancreatitis, at this year's European Association for the Study of Diabetes meeting here. (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - September 20, 2013 Category: Endocrinology Source Type: news
Cardiac Risks of Diabetes Drugs a Focus at EASD
BARCELONA (MedPage Today) -- A major focus of the upcoming meeting of the European Association for the Study of Diabetes here will be the risks and benefits of the incretin-based therapies, according to the chair of the program committee. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 19, 2013 Category: Cardiology Source Type: news
Novel Diabetes Drug Effective in Trial (CME/CE)
(MedPage Today) -- The investigational SGLT2 inhibitor empagliflozin lowers HbA1c as well as the widely used DPP-4 inhibitor sitagliptin (Januvia), and may work better than the incretin stimulator among patients with worse disease control, researchers found. (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - September 10, 2013 Category: Endocrinology Source Type: news
